STAR trial : In the preventive star trial, both tamoxifen and raloxifine (evista) were found to be effective in preventing breast cancer. Statistically, tamoxifen is more effective but also have more side effects. Evista (raloxifene) is only approved in post menopausal female while tamoxifen is approved in pre and post menopausal groups. Evista (raloxifene) is better if there is an osteopenia or osteoporosis present.
Answered 9/16/2017
5.2k views
A doctor has provided 1 answer
2 doctors weighed in across 2 answers
A doctor has provided 1 answer
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question